2-(4,5-二氯-2-硝基苯基)乙酸 | 37777-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(4,5-二氯-2-硝基苯基)乙酸
• 中文别名: 二氯硝基苯乙酸
• 英文名称: 2-nitro-4,5-dichlorophenylacetic acid
• 英文别名: 4,5-dichloro-2-nitrophenylacetic acid；4,5-Dichloro-2-nitro-phenylacetic acid；4,5-Dichlor-2-nitro-phenylessigsaeure；2-(4,5-Dichloro-2-nitrophenyl)acetic acid
• CAS: 37777-90-5
• 化学式: C₈H₅Cl₂NO₄
• 分子量: 250.038
• InChiKey: NIBVBDGBJQMRNF-UHFFFAOYSA-N

物化性质

• 熔点：
  127-130°
• 沸点：
  388.0±37.0 °C(Predicted)
• 密度：
  1.638±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  83.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  2-(4,5-二氯-2-硝基苯基)乙酸 在 platinum(IV) oxide 咪唑 、 硫酸 、 氢气 、 sodium methylate 、 sodium hydride 、 溶剂黄146 、 三氯氧磷 作用下， 以 甲醇 、 1,2-二氯乙烷 、 乙腈 为溶剂， 20.0 ℃ 、275.8 kPa 条件下， 反应 32.0h， 生成 1-(2-deoxy-β-D-erythro-pentofuranosyl)-2,5,6-trichloroindole
  参考文献：
  名称：

  Synthesis and Antiviral Evaluation of Trisubstituted Indole N-Nucleosides as Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole (TCRB)

  摘要：

  2,5,6-Trichloro-1-(beta-D-ribofuranosyl)benzimidazole (TCRB) and 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole (BDCRB) are nucleosides that exhibit strong and selective activity against human cytomegalovirus (HCMV). Selected polyhalogenated indole nucleosides have now been synthesized as 3-deaza analogues of the benzimidazole nucleosides using the sodium salt glycosylation method. 2-Benzylthio-1-[2-deoxy-3,5-bis-O-(4-methylbenzoyl)-beta-D-erythropentofuranosyl]-5,6-dichloroindole (8) was prepared stereoselectively via the coupling of a 2-deoxyribofuranosyl alpha-chloride derivative with the sodium salt of 2-benzylthio-5,6-dichloroindole (5). Compound 8 was then elaborated into the targeted 2-benzylthio-1-(beta-D-ribofuranosyl)-5,6-dichloroindole (18) in five steps. 2,5,6-Trichloro-(1-beta-D-ribofuranosyl)indole (19) was prepared using the same synthetic route with 2,5,6-trichloroindole (6) as the starting material. We were subsequently able to prepare 19 in three steps using a modification of the sodium salt glycosylation method. 2-Bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)indole (25) was also prepared using the same procedures. Target compounds were tested for activity against HCMV, herpes simplex virus type 1 (HSV-1), and human herpes virus six (HHV-6) and for cytotoxicity. All of the compounds were less active against HCMV than TCRB and weakly active or inactive against HSV-1 and HHV-6.

  DOI：

  10.1021/jm990320x
• 作为产物：
  描述：

  3,4-二氯苯乙酸 在 硫酸 、 硝酸 作用下， 以70%的产率得到2-(4,5-二氯-2-硝基苯基)乙酸
  参考文献：
  名称：

  合成破骨细胞抑制剂SB-242784

  摘要：

  破骨细胞抑制剂SB-242784（1）是由关键的吲哚中间体4制备的。有机锡2c与溴化丙烯酸酯11的“ Stille”交叉偶联提供了二烯12，它也是通过烯炔16的还原异构化过程获得的。溴酰胺3是由相应的酸制备7将其容易地从溴丙酮酸获得。

  DOI：

  10.1016/s0040-4039(03)00544-6

文献信息

• Kappa agonist compounds and pharmaceutical formulations thereof
  申请人：——

  公开号：US20030144272A1

  公开（公告）日：2003-07-31

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics are provided. The compounds of formulae I, II, IIA, III, IIIA, IIIB, IIIB-i, IV and IVA have the structure: 1 2 wherein R 1 , R 2 , R 3 , R 4 ; and X, X 4 , X 5 , X 7 , X 9 ; Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物，含有这些化合物的组合物以及使用它们作为镇痛剂的方法。 具有以下结构的化合物I、II、IIA、III、IIIA、IIIB、IIIB-i、IV和IVA： 1 2 其中 R 1 ，R 2 ，R 3 ，R 4 ；和 X，X 4 ，X 5 ，X 7 ，X 9 ； Y，Z和n如规范中所述。
• Kappa agonist compounds pharmaceutical formulations and method of
  申请人：Adolor Corporation

  公开号：US06057323A1

  公开（公告）日：2000-05-02

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and anti-pruritic agents are provided. The compound of formula I, having the structure: ##STR1## wherein R.sub.1, R.sub.2 ; X; and Ar Y, Z and n are as described in the specification.

  提供具有kappa阿片受体激动剂活性的化合物、含有这些化合物的组合物以及将它们用作镇痛剂和抗瘙痒剂的方法。具有结构的I式化合物：##STR1##其中R.sub.1，R.sub.2；X；和Ar Y，Z和n如规范中描述。
• Aminotetralin derivatives
  申请人：Dr. Karl Thomae GmbH

  公开号：US04584293A1

  公开（公告）日：1986-04-22

  This invention related to new aminotetralin derivatives of formula I ##STR1## wherein ##STR2## B is methylene or, when A is --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --NH--CO-- or --CH.sub.2 --CO--, B can also be carbonyl or thiocarbonyl; E is a C.sub.2 -C.sub.4 straight-chain alkylene, optionally substituted by a C.sub.1 -C.sub.3 alkyl, or is 2-hydroxy-n-propylene, 2-hydroxy-n-butylene or 3-hydroxy-n-butylene; R.sub.1 is hydrogen, fluorine, chlorine, bromine, trifluoromethyl, nitro, amino, C.sub.1 -C.sub.3 alkylamino, C.sub.1 -C.sub.3 dialkylamino, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkylthio, hydroxy, C.sub.1 -C.sub.3 alkoxy or phenyl C.sub.1 -C.sub.3 alkoxy; R.sub.2 is hydrogen, chlorine, bromine, hydroxy, C.sub.1 -C.sub.3 alkoxy phenyl C.sub.1 -C.sub.3 alkoxy, or C.sub.1 -C.sub.3 alkyl or, together with R.sub.1, can be a C.sub.1 -C.sub.2 alkylenedioxy; R.sub.3 and R.sub.4 are each independently selected from hydrogen, fluorine, chlorine, bromine, C.sub.1 -C.sub.3 alkyl, hydroxy, C.sub.1 -C.sub.3 alkoxy, nitro, amino, C.sub.1 -C.sub.3 alkylamino, or C.sub.1 -C.sub.3 dialkylamino, or together can be methylenedioxy; and R.sub.5 is hydrogen, C.sub.3 -C.sub.5 alkenyl, C.sub.1 -C.sub.3 alkyl, or phenyl C.sub.1 -C.sub.3 alkyl, and nontoxic, pharmaceutically acceptable addition salts thereof which have valuable pharmacological properties, particularly a long-lasting heart rate lowering effect and the effect of reducing the O.sub.2 requirement of the heart.

  这项发明涉及公式I的新的氨基四氢萘衍生物，其中B是亚甲基，当A是--CH.sub.2--CH.sub.2--时，B也可以是羰基或硫代羰基；E是一种C.sub.2-C.sub.4直链烷基，可以选择性地被C.sub.1-C.sub.3烷基取代，或者是2-羟基-n-丙烷基，2-羟基-n-丁烷基或3-羟基-n-丁烷基；R.sub.1是氢、氟、氯、溴、三氟甲基、硝基、氨基、C.sub.1-C.sub.3烷基氨基、C.sub.1-C.sub.3二烷基氨基、C.sub.1-C.sub.3烷基、C.sub.1-C.sub.3烷基硫、羟基、C.sub.1-C.sub.3烷氧基或苯基C.sub.1-C.sub.3烷氧基；R.sub.2是氢、氯、溴、羟基、C.sub.1-C.sub.3烷氧基苯基C.sub.1-C.sub.3烷氧基、或C.sub.1-C.sub.3烷基或者与R.sub.1一起可以是C.sub.1-C.sub.2烷二氧基；R.sub.3和R.sub.4各自独立地选自氢、氟、氯、溴、C.sub.1-C.sub.3烷基、羟基、C.sub.1-C.sub.3烷氧基、硝基、氨基、C.sub.1-C.sub.3烷基氨基或C.sub.1-C.sub.3二烷基氨基，或者一起可以是亚甲基二氧基；R.sub.5是氢、C.sub.3-C.sub.5烯丙基、C.sub.1-C.sub.3烷基或苯基C.sub.1-C.sub.3烷基，以及其无毒的、药学上可接受的盐，具有有价值的药理学特性，特别是长效降低心率和减少心脏对O.sub.2需求的作用。
• Antimalarial phenanthrene amino alcohols. 3. Halogen-containing 9-phenanthrenemethanols
  作者：Edward A. Nodiff、Andrew J. Saggiomo、Keiichi Tanabe、Eugene H. Chen、Masafu Shinbo、Mahesh P. Tyagi、Atsuto Kozuka、Hirotaka Otomasu、Basant L. Verma、David Goff

  DOI：10.1021/jm00244a012

  日期：1975.10

  A series of new 9-phenanthrene amino alcohols has been prepared in which each compound bears from one to five halogen or halogen-containing moieties. A number of these compounds are extremely active against Plasmodium berghei in the mouse. Some structural requirements for optimal efficacy are considered.

  已经制备了一系列新的9-菲氨基醇，其中每种化合物带有一个至五个卤素或含卤素的部分。这些化合物中的许多对小鼠中的伯氏疟原虫具有极强的活性。考虑了最佳功效的一些结构要求。
• Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith
  申请人：——

  公开号：US20040220112A1

  公开（公告）日：2004-11-04

  Compounds having kappa opioid agonist activity, compositions containing them and method of using them as analgesics and pruritic agents are provided. The compounds of formulae I, II, III and IV have the structure: 1 wherein X, X 4 , X 5 , X 7 , X 9 ; R 1 , R 2 , R 3 , R 4 ; and Y, Z and n are as described in the specification

  提供具有kappa阿片受体激动剂活性的化合物、包含它们的组合物和使用它们作为镇痛剂和止痒剂的方法。公式I、II、III和IV的化合物具有以下结构：1其中X、X4、X5、X7、X9；R1、R2、R3、R4；以及Y、Z和n的描述如规范中所述。